Antiviral Agents
Antiviral Agents - Related Videos
03:27
Preparing Cells to Analyze Intracellular Uptake and Activity of an Antiviral Agent
0 Views •
2026
Source: Allaire, A., et al. Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus. J. Vis. Exp. (2015).The video demonstrates the procedure for preparing cells to assess the intracellular uptake and activity of an antiviral agent against the hepatitis C virus.
13:00
Engineering Antiviral Agents via Surface Plasmon Resonance
0 Views •
Cited by 3 •
2022
The present protocol describes new tools for SPR binding assays to examine CV-N binding to HA, S glycoprotein, related hybrid-type glycans, and high-mannose oligosaccharides. SPR is used to determine the KD for binding either dimeric or monomeric CV-N to these glycans.
12:02
Assays for the Identification of Novel Antivirals against Bluetongue Virus
0 Views •
Cited by 11 •
2013
Three assays, including the cytopathic effect (CPE)-based assay, dose-response assay and Time-of-Addition (ToA) assay have been developed, optimized, validated and utilized to identify novel antivirals against Bluetongue virus (BTV), as well as to determine the possible Mechanism-of-Action (MoA) for newly identified antivirals.
02:57
Assessing Antiviral Cytokine Production in Response to Viral Infection
0 Views •
2026
Source: Zhang, J., et al. Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production. J. Vis. Exp. (2014)This video demonstrates the process of infecting murine fibroblast cells with herpesvirus and monitoring the resulting antiviral cytokine release and gene expression. It outlines key steps, including viral infection, media collection for cytokine quantification, and cell harvesting for gene expression analysis.
02:48
Determining Antiviral Efficacy of Experimental Drugs Through a Plaque Assay
0 Views •
2025
This video demonstrates the method to perform a plaque assay using a virus obtained from infected porcine cornea. The porcine cornea is used to test the antiviral efficacy of experimental drugs.
FAQs
Target selection follows the viral life cycle rather than a single universal mechanism. An agent may act before genome replication by limiting attachment or entry, during replication by interfering with genome-copying machinery, or later by disrupting protein processing or particle release. Mapping the target to the infection stage helps explain which viral event the compound is intended to restrict.
Enzyme-directed antiviral agents illustrate how a molecular target can produce a defined outcome. Polymerase inhibition can interfere with viral genome replication, whereas protease inhibition can disrupt the processing of viral proteins. Medicinal chemistry then seeks activity against the viral enzyme while limiting effects on host cells, supporting potency and selectivity in the same design.
Molecular structure controls more than antiviral potency. Researchers modify chemical structures to improve how strongly a compound acts, how selectively it distinguishes viral targets from host cells, and how stable, soluble, and deliverable it is. These properties are interconnected design considerations, so a promising agent must be optimized as both a chemical compound and a usable treatment.
An effective development workflow connects a desired viral target with chemical design. Researchers select a life-cycle process or viral enzyme, modify molecular structure, and assess whether the resulting compound offers better potency, selectivity, stability, solubility, or delivery. They also consider toxicity to host cells, because improved antiviral activity alone does not establish a suitable candidate.
Antiviral agents are relevant across several infection settings, including HIV, influenza, hepatitis, and herpesvirus disease. The same broad chemical strategy can therefore be applied to different viral systems, but the selected target depends on the life-cycle stage and molecular machinery available in each infection. This target-centered view connects medicinal chemistry with infectious-disease treatment and prevention.
Research on emerging pathogens and drug-resistant strains places emphasis on adaptable chemical design. Existing targets and mechanisms can guide development, while structural modification may be used to seek stronger activity, better selectivity, or improved delivery. The broader goal is not simply to identify viral inhibition, but to produce compounds whose chemical properties support continued therapeutic development against changing infectious threats.